Introduction
During the last decade transplantation of retinal (RPE) and iris pigment epithelial (IPE) cells has been advocated as a treatment modality for age-related macular degeneration and Parkinson's disease (PD), but transplantation of RPE or IPE cells in age-related macular degeneration patients has resulted only in limited functional rehabilitation and transplantation of RPE cells in Parkinson's patients does not alleviate symptoms. [1] [2] [3] [4] [5] [6] [7] [8] [9] Since in vivo an equilibrium of neurotrophic factors, such as pigment epithelium-derived factor (PEDF), fibroblast growth factor, platelet-derived growth factor and others, supports the survival of neural tissues, it may be necessary to transplant cells that have been genetically modified to express these factors to achieve optimal functional improvement. In fact, in vitro and in vivo studies have shown that supplementation with various growth factors prevents or delays photoreceptor degeneration and increases the function of dopaminergic tissue in animal models of retinal degeneration and PD. [10] [11] [12] [13] [14] Even though it is possible to administer factors affecting retinal and dopaminergic cells by injection directly into the appropriate anatomical loci, repetitive injections would be required to maintain an effective concentration of such factors. However, repetitive injections are not realistic, as they are fraught with significant risk of side effects and non-compliance. The most effective way to apply any biological modifier would be the use of a continuous slow-release system. A number of slow-release, implantable materials and pumps have been developed. However, these are not suitable to implant into very small spaces, as they could only carry small amounts of the substance to be released and would have to be replaced frequently by surgical means. The most obvious and appropriate system for the slow release of a biological modifier would be cells that express such biological modifier. For example, islet cells that express and secrete insulin have been used to deliver insulin in diabetic patients 15 and recently the use of nonvirally transfected autologous liver cells producing insulin has been suggested. 16 The most ideal system for subretinal delivery of bioactive factors would be to transfect RPE cells with the appropriate factors and transplant them into the subretinal space. However, allogeneic RPE cells are rejected and autologous RPE cells are difficult to obtain. A good alternative to RPE cells are autologous IPE cells, which can be easily harvested from a patient by an iridectomy and expanded in cell culture. [17] [18] [19] [20] Submacular transplantation of autologous IPE cells has been examined in a number of experimental and clinical studies as a treatment for exudative age-related macular degenera-tion, 7, 12, [21] [22] [23] [24] [25] and as they produce and secrete a variety of neurotrophic factors, IPE cells have also been suggested for transplantation into the cerebrum to treat neurodegenerative disorders such as PD. 26 After transplantation, autologous IPE cells integrate within the host tissue without evidence of rejection and have been shown to survive for at least 8 weeks in the corpus striatum 26 and up to 3 years in the subretinal space. 7, 23, 27 The long-term survival of autologous IPE cells in the subretinal space makes these cells suitable as a delivery system of neuroprotective factors. 26, 28 Using a viral vector, Semkova et al. 12 transfected IPE cells with PEDF, an antiangiogenic and neuroprotective factor constitutively expressed by RPE cells, and have shown that the transplanted, modified IPE cells survive in the subretinal space. However, there are substantial impediments to the use of viral vectors for the genetic manipulation of cells to be transplanted in vivo, specifically, difficulties in reproducible production and quality of transfected cells, as well as possible immune reactions and toxicity. Nonviral vectors provide easier production without possible complications of immune reactions, toxicity or the influence that viral gene products may have on cellular functions, but are limited by low efficiency. However, transfection efficiency can be improved significantly by electroporation or lipofection.
Electroporation, which takes advantage of the permeabilization of cell membranes that occurs after the controlled application of an electric field, has been used to transfect cells in vitro 29 as well as to transfer specific genes in vivo. 30, 31 Lipofection, which takes advantage of the fact that cationic lipids protect DNA from degradation and facilitate endocytosis, has also been used to enhance gene transfer in vitro and in vivo. 32, 33 In vivo electroporation and lipofection have been shown to allow efficient transfer of the LacZ gene in RPE cells. 34 In this study, we have explored the use of lipofection and electroporation by nucleofection to enhance transfection of the genes for green fluorescent protein (GFP) and PEDF in ARPE-19 cells, primary RPE and IPE cells. Our findings show that nucleofection results in efficient transfection and stable expression of these genes. The efficient non-viral transfection of autologous IPE cells presents an opportunity for the clinical application of genetically modified IPE cells for the treatment of degenerative diseases without the complications that may result from virally mediated gene transfer.
Results

Transfection efficiency
Transfection with the plasmid encoding maxGFP was used to determine the most efficient technique to transfect ARPE-19 cells, primary RPE and IPE cells. Using nucleofection, 80% of ARPE-19 cells were transfected, as evidenced by fluorescence microscopy 24 h after exposure to the pmaxGFP plasmid ( Figure 1a 
Discussion
Gene therapy has long been thought to be the ultimate means for treating any number of diseases afflicting man. However attractive such a hypothesis may be, techni- 
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cally it has been difficult to use gene therapy to achieve substantial treatments. In ocular and other neurodegenerative diseases, gene therapy has been attempted in animal models of human diseases with some success. [36] [37] [38] [39] In these studies the gene was introduced into the appropriate tissues using viral vectors.
However, the use of viral vectors presents significant risks. In fact, after intravitreal injection, the viral genome was found widely disseminated in other organs and tissues, such as the brain, lung, liver, kidney, testis, heart, spleen and muscle. 40 In the trial reported by Worgall et al., 41 there were serious adverse effects including humoral response to the vector and other adverse side effects of unknown etiology. To avoid the use of viral vectors, compacted DNA nanoparticles have been used to deliver genetic information. Farjo et al. 42 have shown that compacted DNA nanoparticles are efficient at delivering genetic information, but lack specificity. The subretinal injection of compacted DNA particles carrying GFP resulted in the expression of GFP in photoreceptors, RPE, inner nuclear layer and ganglion cell layer. When injected intravitreally, GFP expression was found in the cornea, trabecular meshwork and lens. 42 To avoid the limitations associated with viral vectors as well as the inefficient transfection using lipofection, we have investigated the use of nucleofection to transfect Non As the ultimate goal of transfection is to be able to deliver a biologically active substance to a specific site, for example, PEDF to the subretinal space or CNS, we transfected ARPE-19 cells, primary RPE and IPE cells with recombinant human PEDF. Transfection of ARPE-19 cells with the circular or linearized forms of the plasmids pMS-N-PEDF-EGFP-MH, pMS-L-EGFP-PEDF-H-IV and pMS-N-PEDF-H-IV resulted in the expression of the appropriate PEDF fusion proteins. At 3 days after Figure 5 Western blot analysis of Ni-NTA-purified pigment epithelium-derived factor (PEDF) fusion proteins from cell culture supernatants of Zeocin-selected ARPE-19 cells transfected with linearized recombinant PEDF plasmids. The PEDF fusion proteins N-PEDF-H-IV and L-EGFP-PEDF-H-IV are expressed at similar levels after 26 and 28 passages and 35 and 37 passages, respectively, in the presence or absence of Zeocin. In these experiments, care was taken to load all gels with 10 ml of Ni-NTA-purified protein solution isolated from 900 ml of culture supernatant using the standardized protocol (see Materials and methods). Non-viral transfection of ocular pigment cells G Thumann et al transfection with the circular form of the pMS plasmids, ARPE-19 cells expressed significantly higher levels of the PEDF fusion proteins than the cells transfected with the linearized plasmids. However, unlike the transfection with the linearized plasmids, there was a marked decrease in expression of the PEDF fusion proteins by the cells transfected with the circular plasmids by 18 days, suggesting that transfection with the circular plasmids was more efficient, but less stable. Transfection with the linearized plasmids resulted in stable clones expressing PEDF fusion proteins for up to 37 passages.
We have also shown that it is feasible to transfect primary bovine RPE and IPE cells with high efficiency using the nucleofection technology. Transfection of these cells with the plasmid pMS-L-EGFP-PEDF-H-IV resulted in the efficient expression of the PEDF fusion protein.
Our data also show that the PEDF and PEDF-GFP fusion proteins, secreted into the culture media, are biologically active as evidenced by the upregulation of the zinc transporter ZIP2 mRNA.
The ability to transfect RPE and IPE cells stably with recombinant PEDF that is secreted into the culture media as a biologically active product, without the aid of viral vectors, is an important initial step in the application of tissue engineering in the treatment of neurodegenerative diseases. Now that we have shown that the non-viral transfection of primary IPE cells with recombinant neuroprotective factors is feasible and efficient, the challenge of using IPE cells-to develop 'designer cells' for the treatment of specific neurodegenerative diseases-will be the generation of a substratum appropriate to the tissue into which the cells are to be transplanted. For example in age-related macular degeneration, autologous IPE cells will need a substratum that will serve as a temporary prosthesis to allow the cells to reconstruct Bruch's membrane before it is degraded and allow the cells to integrate into the neural retina-Bruch's membrane-choroid complex. On the other hand, for PD it is desirable that the substratum consists of microspherelike structures that are compatible with the corpus striatum, would prevent cell migration away from the implantation site and would allow secreted neuromodulators to freely diffuse in a three-dimensional pattern. Initial studies have shown that an ultrathin collagen type 1 membrane may be appropriate for subretinal transplantation, 43 as it becomes degraded with time, thus allowing the transplanted cells not only to replace degenerated cells, but also to restructure the substratum for proper cell attachment and function. For neurodegenerative diseases, such as PD or Alzheimer's disease, a biodegradable substratum may not be as important as the ability of the transplanted cells to act as an in situ bioreactor to deliver neuroprotective and/or neurogenic trophic factors to lesioned brain areas. For this purpose tridimensional, porous scaffolds, constructed of electrospun nanofibers of a non-biodegradable material, are being investigated.
Materials and methods
Cell culture
Porcine and bovine eyes were obtained from a local abattoir. To isolate RPE and IPE cells, the anterior segment was cut approximately 3.5 mm posterior to the limbus and the iris was dissected from the ciliary body using a scalpel. After incubation of the iris in 0.25% trypsin+0.2% EDTA (PAA Laboratories, Pasching, Austria) for 15 min at 37 1C, IPE cells were isolated by gently brushing the posterior surface of the iris with a firepolished glass spatula. The detached cells were centrifuged at 1000 r.p.m. for 10 min, and the cell pellet was suspended in DMEM/Ham's F-12 (Biochrom AG, Berlin, Germany) supplemented with 10% fetal bovine serum (PAA Laboratories), 80 U ml À1 penicillin and 80 U ml À1 streptomycin (Lonza, Basel, Switzerland). The cells were used immediately for transfection experiments or placed in culture for 8 days before being used for transfection. For RPE isolation the vitreous and the retina were removed and the posterior eyecup was filled with 0.25% trypsin+0.2% EDTA and incubated at 37 1C. After 15 min the trypsin solution was removed and the RPE cells were dislodged by trituration in complete medium (DMEM/ Ham's F-12 supplemented with 80 U ml À1 penicillin, 80 U ml À1 streptomycin and 10% fetal bovine serum). The mixture was centrifuged at 1000 r.p.m. for 10 min, the cell pellet was suspended in complete medium, and the cells were used immediately for transfection experiments or cultured for 8 days before being used for transfection. Cell cultures were maintained at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 , and medium was changed twice a week. Cells were passaged using standard procedures, namely cells were trypsinized, suspended and washed once in appropriate complete medium and passaged at a ratio of 1:3. ARPE-19 cells (ATCC No.: CRL-2302) and HEK293 cells (ATCC No.: CRL-1573) were maintained and passaged weekly according to the manufacturer's protocol (1:10 ARPE-19; 1:6 HEK293). Cell numbers were determined in an aliquot of the cell suspension using a hemocytometer.
Cell proliferation was monitored with crystal violet everyday for 6 days beginning at day 2 of culture. Briefly, the medium was removed and 100 ml crystal violet solution (0.5% in 20% methanol) was added. After 10 min the cells were rinsed with water. After overnight drying 50 ml sodium citrate solution (10 mM in 50% ethanol) was added to each plate and the absorbance was measured at 595 nm using an ELISA reader.
Construction of recombinant PEDF plasmids
Two plasmids expressing PEDF proteins fused to EGFP (pMS-N-PEDF-EGFP-MH and pMS-L-EGFP-PEDF-H-IV)
and one expressing PEDF (pMS-N-PEDF-H-IV) were cloned. The PEDF sequence was amplified from the cDNA of APRE-19 cells with gene-specific primers and extended by appropriate restriction enzyme sequences for subsequent cloning into pMS plasmids as described previously. 44, 45 In the first PCR reaction the PEDF gene was fitted with NheI (n-primer-nhe-pedf: 5 0 -acccaagctg gctagccaccATGCAGGCCCTGGTGCTACTC-3 0 ) and NotI (c-primer-pedf-not: 5 0 -gttcgggccctgcggccgcGGGGCCCC TGGGGTCCAGAATC-3 0 ) restriction sites. This enabled the insertion of the PEDF gene with its native leader sequence by NheI/NotI restriction-mediated cloning into the plasmids pMS-L-A5-EGFP-MH and pMS-L-EGFP-A5-H-IV, 44 resulting in the two plasmids pMS-N-PEDF-EGFP-MH, which encoded a C-terminal PEDF fused to EGFP followed by a tandem Myc/His-tag, and pMS-N-PEDF-H-IV, which encoded PEDF only fitted with a His-
For the PEDF cloning with a N-terminal EGFP fusion, the PEDF gene was amplified without its native leader sequence but with a 5 0 CelII restriction site (nprimer-cel-pedf: 5 0 -atccaaactagctgagcaCCAGAACCCTG CCAGCCCCCCG-3 0 ). After CelII/NotI restriction-mediated replacement of Annexin A5 in the plasmid pMS-L-EGFP-A5-H-IV, the pMS-L-EGFP-PEDF-H-IV plasmid was obtained, whereas secretion of the L-EGFP-PEDF-H-IV fusion protein was initiated by a murine Igk-leader sequence. In all plasmids, gene expression was under the control of a constitutive CMV promoter and a Zeocin resistance gene facilitated the selection of transfected cells.
Recombinant plasmids were extracted under ampicillin selection from positive E. coli clones and characterized by digestion with appropriate restriction enzymes. To verify cloning, all plasmids were sequenced at Eurofins MWG Operon (Ebersberg, Germany). Beside plasmid primers, the specific PEDF amplification primers were used.
Before nucleofection, some PEDF-encoding plasmids were linearized by PvuI restriction, whose consensus site is located outside the eukaryotic relevant operons in the ampicillin resistance gene.
Nucleofection
The plasmid pmaxGFP (circular), encoding GFP from the copepod Pontellina plumata (maxGFP), was obtained from Amaxa AG (Cologne, Germany). The PEDF plasmids were constructed as described above. For nucleofection, 2-5 mg of each plasmid was added to 10 6 ARPE-19 cells and 10 6 primary RPE or IPE cells. A total of 100 ml of cell-type-specific nucleofector solution (Amaxa) were added to each cell sample and an electric pulse was applied using the Nucleofector I (Amaxa: program X-01 for ARPE-19 and program T-23 for primary RPE and IPE cells). Immediately after nucleofection, cells were transferred into 12-well tissue culture plates in 2 ml of complete medium and maintained at 37 1C in a humidified atmosphere of 95% air and 5% CO 2 . Two controls were routinely carried out, namely cells exposed to the same electric field as the experimental cells but without the addition of plasmid DNA and cells exposed to plasmid DNA but without electric field exposure.
After transfection ARPE-19, RPE and IPE cells were passaged weekly. Some RPE and IPE cells were not passaged but maintained in the same culture dish in medium containing 5% fetal bovine serum.
Lipofection
For transfection experiments using lipofection two different reagents were tested: Lipofectamine LTX (Invitrogen) and Metafectene Pro (Biontex Laboratories, Martinsried, Germany). Lipofectamine LTX: Cells were plated in 24-well plates in 1 ml complete medium at a density of 120 000 cells per cm 2 for ARPE-19 cells and 250 000 cells per cm 2 for primary RPE and IPE cells. After 24 h, cells were incubated with 100 ml plasmid DNALipofectamine LTX complex for 30 min at room temperature. Metafectene Pro: After 24 h of culture (see above) a plasmid DNA-Metafectene Pro solution was prepared according to the manufacturer's protocol and added drop wise to each well. Cultures treated with the same solutions either without plasmid DNA or without the lipofection reagents were used as controls.
Transfection efficiency
Transfection efficiencies were determined by fluorescence microscopy 24 h after exposing cells to the plasmid pmaxGFP. For efficiencies below 5%, all GFP-positive cells were counted. For efficiencies above 5%, GFPpositive cells were counted in 10 randomly selected microscopic fields. The transfection efficiencies are expressed as the ratio of GFP-positive cells compared with the total cell number, which was determined by counting the Hoechst 33342-stained cell nuclei.
Establishing cultures of transfected HEK293 and ARPE-19 cells
At 3 days after transfection, cell culture supernatants were analyzed for secretion of recombinant PEDF. Subsequently, the transfected cells were transferred into cell culture flasks (75 cm 2 ) and grown in complete medium supplemented with 100 mg ml À1 Zeocin in a humidified atmosphere of 95% air and 5% CO 2 . After 2 weeks, distinct green fluorescent (transfected) colonies were identified by fluorescence microscopy, isolated and cultured to establish transfected cell populations.
Protein purification
Purification of the His-tagged PEDF fusion proteins was accomplished by Ni-NTA metal affinity chromatography (Qiagen, Hilden, Germany). Cell culture media were collected and centrifuged for 10 min at 1100 r.p.m. at 4 1C. The supernatants were collected and stored at 4 1C until use. For western blot analysis, 900 ml of the cleared cell culture media were mixed with 300 ml of 4Â incubation buffer (200 mM NaH 2 PO 4 , pH 8.0, 1.2 M NaCl and 40 mM imidazole) and 30 ml of 50% Ni-NTA slurry. After incubation for 1 h at room temperature, the Ni-NTA resin was pelleted by centrifugation (1 min at 5000 r.p.m.) and washed twice with 175 ml 1 Â incubation buffer. Bound protein was eluted by incubation with 30 ml of elution buffer (50 mM NaH 2 PO 4 , pH 8.0, 300 mM NaCl and 250 mM imidazole) for 20 min at room temperature. For functional assays the His-tagged PEDF fusion proteins were purified using Ni-NTA spin columns (Qiagen). 3600 ml of cleared cell culture media were mixed with 1200 ml of 4 Â incubation buffer and applied to the columns. Bound protein was eluted with 100 ml of elution buffer and stored on ice until use.
Upregulation of ZIP2 gene expression by PEDF and PEDF-GFP fusion proteins
To determine the biological activity of PEDF and PEDF-GFP fusion proteins, we measured the upregulation of ZIP2 mRNA according to the methods of Leung et al.
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ARPE-19 cells were grown to a confluent monolayer, washed twice with zinc-and serum-free MEM, and cultured in zinc-and serum-free MEM in the presence of 200 ng ml À1 PEDF, 1.2 mg ml À1 purified N-PEDF-EGFP-MH fusion protein, 3.2 mg ml À1 purified L-EGFP-PEDF-H-IV fusion protein or 3.3 mg ml À1 purified N-PEDF-H-IV fusion protein. ARPE-19 cells cultured in zinc-and serum-free MEM without any additive were used as controls. After 48 h, cultures were harvested and total RNA was isolated using the RNeasy Mini Kit (Qiagen) together with the RNase-free DNase Set (Qiagen) according to the protocol of the manufacturer. Reverse transcription was carried out on 1 mg total RNA using the 46, 47 was used. The data of the treated cells (medium with additives) were presented as change in gene expression normalized to the internal control genes (DCP) and relative to the data of the untreated cells (medium without additive; DDCP). By definition, the DDCP for untreated cells equals 0, resulting in a relative gene expression rate of 1. For treated cells, a ratio of 1 indicates similar gene expression, whereas a ratio greater than 1 is equated with a higher gene expression rate.
Western blot analysis
For SDS-polyacrylamide gel electrophoresis, 10 ml of Ni-NTA-purified protein were mixed with 2 Â SDS sample buffer, 48 heated for 5 min at 95 1C and separated on a 10% SDS-polyacrylamide gel electrophoresis gel. After electrophoresis, the proteins were transferred onto a 0.45 mm pore-size nitrocellulose membrane (Whatman, Maidstone, Kent, UK) using the semidry blotting technique and stained with Ponceau S to confirm the transfer. Blots blocked with 3% BSA (bovine serum albumin)/TBS overnight at 4 1C were incubated for 2 h at room temperature with anti-Penta-His antibodies (mouse monoclonal, 1:1000; Qiagen) or (for confirmation) anti-PEDF (I-15) (goat polyclonal, 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted in 3% BSA/TBS. Afterwards, the blots were incubated for 1 h at room temperature with horseradish peroxidase-conjugated anti-mouse antibodies (rabbit polyclonal, 1:1000; Dako, Glostrup, Denmark) for Penta-His and with horseradish peroxidase-conjugated anti-goat antibodies (donkey, 1:1000; Santa Cruz Biotechnology) for PEDF diluted in 10% milk powder/TBS. Protein bands were visualized by chemiluminescence using the LAS-3000 imaging system (FujiFilm, Tokyo, Japan).
